| ONC201 and imipridones: Anti-cancer compounds with clinical efficacy VV Prabhu, S Morrow, AR Kawakibi, L Zhou, M Ralff, J Ray, A Jhaveri, ... Neoplasia 22 (12), 725-744, 2020 | 113 | 2020 |
| Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma E Cantor, K Wierzbicki, RS Tarapore, K Ravi, C Thomas, R Cartaxo, ... Neuro-oncology 24 (8), 1366-1374, 2022 | 50 | 2022 |
| Targeting and therapeutic monitoring of H3K27M-mutant glioma K Wierzbicki, K Ravi, A Franson, A Bruzek, E Cantor, M Harris, MJ Homan, ... Current oncology reports 22, 1-9, 2020 | 46 | 2020 |
| Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways S Venneti, AR Kawakibi, S Ji, SM Waszak, SR Sweha, M Mota, M Pun, ... Cancer discovery 13 (11), 2370-2393, 2023 | 31 | 2023 |
| Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine K Schwark, D Messinger, JR Cummings, J Bradin, A Kawakibi, CM Babila, ... Frontiers in Oncology 12, 922928, 2022 | 7 | 2022 |
| Perceived barriers to the de-implementation of routine preoperative history & physicals preceding low-risk ambulatory procedures: a qualitative study of surgeon perspectives AS Baskin, AI Mansour, AR Kawakibi, PJ Das, AE Rios, J Miller, A Cuttitta, ... Journal of Surgical Research 270, 359-368, 2022 | 5 | 2022 |
| HGG-18. Clinical Efficacy of ONC201 in thalamic H3 K27M-mutant glioma AR Kawakibi, RS Tarapore, S Gardner, A Chi, S Kurz, PY Wen, ... Neuro-Oncology 22 (Supplement_3), iii347-iii347, 2020 | 5 | 2020 |
| CTNI-61. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA AR Kawakibi, R Tarapore, S Gardner, A Chi, S Kurz, PY Wen, ... Neuro-Oncology 24 (Supplement_7), vii86-vii87, 2022 | 3 | 2022 |
| EXTH-74. Ind-enabling characterization of dual DRD2-and ClpP-targeting agent ONC206 as the next imipridone for clinical neuro-oncologY V Prabhu, S Morrow, AR Kawakibi, Y Jitkova, J Jung, N Madhukar, ... Neuro-oncology 22 (Supplement_2), ii103-ii103, 2020 | 3 | 2020 |
| IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology VV Prabhu, AR Kawakibi, N Madhukar, MJ Garnett, U McDermott, ... Cancer Research 79 (13_Supplement), 3877-3877, 2019 | 3 | 2019 |
| PDCT-12. Clinical efficacy of onc201 in thalamic H3 K27M-mutant glioma A Rahman Kawakibi, S Gardner, A Chi, S Kurz, P Wen, ... Neuro-oncology 21 (Supplement_6), vi186-vi186, 2019 | 2 | 2019 |
| Defining structure activity relationships for GPCR engagement and anti-cancer efficacy of imipridone small molecules VV Prabhu, AR Kawakibi, NS Madhukar, L Anantharaman, S Deacon, ... Cancer Research 79 (13_Supplement), 2749-2749, 2019 | 2 | 2019 |
| DDRE-33. MOLECULAR DIFFERENTIATION OF IMIPRIDONES ONC201 AND ONC206 V Prabhu, C Cuoco, J Jung, S Morrow, AR Kawakibi, B Willette, M Day, ... Neuro-Oncology 22 (Supplement_2), ii68-ii68, 2020 | 1 | 2020 |
| EXTH-71. Ind-enabling characterization of ONC206 as the next bitopic DRD2 antagonist for neuro-oncology V Prabhu, AR Kawakibi, N Madhukar, M Garnett, U McDermott, C Benes, ... Neuro-oncology 21 (Suppl 6), vi97, 2019 | 1 | 2019 |
| DDIS-20. Imipridone structure activity relationship uncovers ONC206 as the next bitopic DRD2 antagonist for oncology with differentiated receptor pharmacology V Prabhu, C Cuoco, J Jung, AR Kawakibi, B Willette, M Day, ... Neuro-Oncology 21 (Suppl 6), vi67, 2019 | 1 | 2019 |
| TMET-02. CLINICAL EFFICACY OF ONC201 IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS IS DRIVEN BY DISRUPTION OF INTEGRATED METABOLIC AND EPIGENETIC PATHWAYS S Venneti, AR Kawakibi, S Ji, S Waszak, S Sweha, M Mota, M Pun, ... Neuro-Oncology 25 (Supplement_5), v272-v272, 2023 | | 2023 |
| Novel indications for autologous fat grafting in reconstruction: scleroderma AR Kawakibi, AN Khouri, PS Cederna, AL Strong | | 2023 |
| BIOM-28. SERIAL PLASMA AND CSF CELL-FREE TUMOR DNA (cf-tDNA) TRACKING IN DIFFUSE MIDLINE GLIOMA PATIENTS UNDERGOING TREATMENT WITH ONC201 E Cantor, K Wierzbicki, R Tarapore, K Ravi, J Wadden, C Babilla, ... Neuro-Oncology 23 (Supplement_6), vi16-vi17, 2021 | | 2021 |
| EPCT-03. SERIAL PLASMA AND CSF CELL-FREE TUMOR DNA (CF-TDNA) TRACKING IN DIFFUSE MIDLINE GLIOMA PATIENTS UNDERGOING TREATMENT WITH ONC201 E Cantor, K Wierzbicki, RS Tarapore, C Thomas, R Cartaxo, VN Yadav, ... Neuro-oncology 23 (Supplement_1), i46-i47, 2021 | | 2021 |
| CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA A Rahman Kawakibi, RS Tarapore, S Gardner, C Thomas, R Cartaxo, ... Neuro-oncology 22 (Supplement_2), ii45-ii46, 2020 | | 2020 |
